Report cover image

Global Monoclonal Antibody Drugs For Cancer Market Research Report 2025(Status and Outlook)

Publisher Bosson Research
Published Aug 03, 2025
Length 170 Pages
SKU # BOSS20301610

Description

Report Overview

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The global Monoclonal Antibody Drugs For Cancer market size was estimated at USD 103210.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.50% during the forecast period.

This report provides a deep insight into the global Monoclonal Antibody Drugs For Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Monoclonal Antibody Drugs For Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Monoclonal Antibody Drugs For Cancer market in any manner.

Global Monoclonal Antibody Drugs For Cancer Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

Market Segmentation (by Type)

Mouse-derived Antibodies

Chimeric Antibodies

Humanized Antibodies

Market Segmentation (by Application)

Lung Cancer

Breast Cancer

Prostate Cancer

Blood-related Cancer

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Monoclonal Antibody Drugs For Cancer Market

Overview of the regional outlook of the Monoclonal Antibody Drugs For Cancer Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Monoclonal Antibody Drugs For Cancer Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Monoclonal Antibody Drugs For Cancer, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Table of Contents

170 Pages
1 Research Methodology And Statistical Scope
1.1 Market Definition And Statistical Scope Of Monoclonal Antibody Drugs For Cancer
1.2 Key Market Segments
1.2.1 Monoclonal Antibody Drugs For Cancer Segment By Type
1.2.2 Monoclonal Antibody Drugs For Cancer Segment By Application
1.3 Methodology & Sources Of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown And Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Monoclonal Antibody Drugs For Cancer Market Overview
2.1 Global Market Overview
2.1.1 Global Monoclonal Antibody Drugs For Cancer Market Size (M Usd) Estimates And Forecasts (2020-2033)
2.1.2 Global Monoclonal Antibody Drugs For Cancer Sales Estimates And Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size By Region
3 Monoclonal Antibody Drugs For Cancer Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Monoclonal Antibody Drugs For Cancer Product Life Cycle
3.3 Global Monoclonal Antibody Drugs For Cancer Sales By Manufacturers (2020-2025)
3.4 Global Monoclonal Antibody Drugs For Cancer Revenue Market Share By Manufacturers (2020-2025)
3.5 Monoclonal Antibody Drugs For Cancer Market Share By Company Type (Tier 1, Tier 2, And Tier 3)
3.6 Global Monoclonal Antibody Drugs For Cancer Average Price By Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, And Product Types
3.8 Monoclonal Antibody Drugs For Cancer Market Competitive Situation And Trends
3.8.1 Monoclonal Antibody Drugs For Cancer Market Concentration Rate
3.8.2 Global 5 And 10 Largest Monoclonal Antibody Drugs For Cancer Players Market Share By Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Monoclonal Antibody Drugs For Cancer Industry Chain Analysis
4.1 Monoclonal Antibody Drugs For Cancer Industry Chain Analysis
4.2 Market Overview Of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development And Dynamics Of Monoclonal Antibody Drugs For Cancer Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 Pest Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Monoclonal Antibody Drugs For Cancer Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions And Their Impacts To Monoclonal Antibody Drugs For Cancer Market
5.7 Esg Ratings Of Leading Companies
6 Monoclonal Antibody Drugs For Cancer Market Segmentation By Type
6.1 Evaluation Matrix Of Segment Market Development Potential (Type)
6.2 Global Monoclonal Antibody Drugs For Cancer Sales Market Share By Type (2020-2025)
6.3 Global Monoclonal Antibody Drugs For Cancer Market Size Market Share By Type (2020-2025)
6.4 Global Monoclonal Antibody Drugs For Cancer Price By Type (2020-2025)
7 Monoclonal Antibody Drugs For Cancer Market Segmentation By Application
7.1 Evaluation Matrix Of Segment Market Development Potential (Application)
7.2 Global Monoclonal Antibody Drugs For Cancer Market Sales By Application (2020-2025)
7.3 Global Monoclonal Antibody Drugs For Cancer Market Size (M Usd) By Application (2020-2025)
7.4 Global Monoclonal Antibody Drugs For Cancer Sales Growth Rate By Application (2020-2025)
8 Monoclonal Antibody Drugs For Cancer Market Sales By Region
8.1 Global Monoclonal Antibody Drugs For Cancer Sales By Region
8.1.1 Global Monoclonal Antibody Drugs For Cancer Sales By Region
8.1.2 Global Monoclonal Antibody Drugs For Cancer Sales Market Share By Region
8.2 Global Monoclonal Antibody Drugs For Cancer Market Size By Region
8.2.1 Global Monoclonal Antibody Drugs For Cancer Market Size By Region
8.2.2 Global Monoclonal Antibody Drugs For Cancer Market Size Market Share By Region
8.3 North America
8.3.1 North America Monoclonal Antibody Drugs For Cancer Sales By Country
8.3.2 North America Monoclonal Antibody Drugs For Cancer Market Size By Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Monoclonal Antibody Drugs For Cancer Sales By Country
8.4.2 Europe Monoclonal Antibody Drugs For Cancer Market Size By Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Monoclonal Antibody Drugs For Cancer Sales By Region
8.5.2 Asia Pacific Monoclonal Antibody Drugs For Cancer Market Size By Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Monoclonal Antibody Drugs For Cancer Sales By Country
8.6.2 South America Monoclonal Antibody Drugs For Cancer Market Size By Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East And Africa
8.7.1 Middle East And Africa Monoclonal Antibody Drugs For Cancer Sales By Region
8.7.2 Middle East And Africa Monoclonal Antibody Drugs For Cancer Market Size By Region
8.7.3 Saudi Arabia Market Overview
8.7.4 Uae Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Monoclonal Antibody Drugs For Cancer Market Production By Region
9.1 Global Production Of Monoclonal Antibody Drugs For Cancer By Region(2020-2025)
9.2 Global Monoclonal Antibody Drugs For Cancer Revenue Market Share By Region (2020-2025)
9.3 Global Monoclonal Antibody Drugs For Cancer Production, Revenue, Price And Gross Margin (2020-2025)
9.4 North America Monoclonal Antibody Drugs For Cancer Production
9.4.1 North America Monoclonal Antibody Drugs For Cancer Production Growth Rate (2020-2025)
9.4.2 North America Monoclonal Antibody Drugs For Cancer Production, Revenue, Price And Gross Margin (2020-2025)
9.5 Europe Monoclonal Antibody Drugs For Cancer Production
9.5.1 Europe Monoclonal Antibody Drugs For Cancer Production Growth Rate (2020-2025)
9.5.2 Europe Monoclonal Antibody Drugs For Cancer Production, Revenue, Price And Gross Margin (2020-2025)
9.6 Japan Monoclonal Antibody Drugs For Cancer Production (2020-2025)
9.6.1 Japan Monoclonal Antibody Drugs For Cancer Production Growth Rate (2020-2025)
9.6.2 Japan Monoclonal Antibody Drugs For Cancer Production, Revenue, Price And Gross Margin (2020-2025)
9.7 China Monoclonal Antibody Drugs For Cancer Production (2020-2025)
9.7.1 China Monoclonal Antibody Drugs For Cancer Production Growth Rate (2020-2025)
9.7.2 China Monoclonal Antibody Drugs For Cancer Production, Revenue, Price And Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Johnson And Johnson
10.1.1 Johnson And Johnson Basic Information
10.1.2 Johnson And Johnson Monoclonal Antibody Drugs For Cancer Product Overview
10.1.3 Johnson And Johnson Monoclonal Antibody Drugs For Cancer Product Market Performance
10.1.4 Johnson And Johnson Business Overview
10.1.5 Johnson And Johnson Swot Analysis
10.1.6 Johnson And Johnson Recent Developments
10.2 Novartis
10.2.1 Novartis Basic Information
10.2.2 Novartis Monoclonal Antibody Drugs For Cancer Product Overview
10.2.3 Novartis Monoclonal Antibody Drugs For Cancer Product Market Performance
10.2.4 Novartis Business Overview
10.2.5 Novartis Swot Analysis
10.2.6 Novartis Recent Developments
10.3 Gilead Sciences
10.3.1 Gilead Sciences Basic Information
10.3.2 Gilead Sciences Monoclonal Antibody Drugs For Cancer Product Overview
10.3.3 Gilead Sciences Monoclonal Antibody Drugs For Cancer Product Market Performance
10.3.4 Gilead Sciences Business Overview
10.3.5 Gilead Sciences Swot Analysis
10.3.6 Gilead Sciences Recent Developments
10.4 Roche
10.4.1 Roche Basic Information
10.4.2 Roche Monoclonal Antibody Drugs For Cancer Product Overview
10.4.3 Roche Monoclonal Antibody Drugs For Cancer Product Market Performance
10.4.4 Roche Business Overview
10.4.5 Roche Recent Developments
10.5 Bristol-myers Squibb
10.5.1 Bristol-myers Squibb Basic Information
10.5.2 Bristol-myers Squibb Monoclonal Antibody Drugs For Cancer Product Overview
10.5.3 Bristol-myers Squibb Monoclonal Antibody Drugs For Cancer Product Market Performance
10.5.4 Bristol-myers Squibb Business Overview
10.5.5 Bristol-myers Squibb Recent Developments
10.6 Amgen
10.6.1 Amgen Basic Information
10.6.2 Amgen Monoclonal Antibody Drugs For Cancer Product Overview
10.6.3 Amgen Monoclonal Antibody Drugs For Cancer Product Market Performance
10.6.4 Amgen Business Overview
10.6.5 Amgen Recent Developments
10.7 Astrazeneca
10.7.1 Astrazeneca Basic Information
10.7.2 Astrazeneca Monoclonal Antibody Drugs For Cancer Product Overview
10.7.3 Astrazeneca Monoclonal Antibody Drugs For Cancer Product Market Performance
10.7.4 Astrazeneca Business Overview
10.7.5 Astrazeneca Recent Developments
10.8 Merck And Co
10.8.1 Merck And Co Basic Information
10.8.2 Merck And Co Monoclonal Antibody Drugs For Cancer Product Overview
10.8.3 Merck And Co Monoclonal Antibody Drugs For Cancer Product Market Performance
10.8.4 Merck And Co Business Overview
10.8.5 Merck And Co Recent Developments
10.9 Takeda
10.9.1 Takeda Basic Information
10.9.2 Takeda Monoclonal Antibody Drugs For Cancer Product Overview
10.9.3 Takeda Monoclonal Antibody Drugs For Cancer Product Market Performance
10.9.4 Takeda Business Overview
10.9.5 Takeda Recent Developments
10.10 Merck Kgaa
10.10.1 Merck Kgaa Basic Information
10.10.2 Merck Kgaa Monoclonal Antibody Drugs For Cancer Product Overview
10.10.3 Merck Kgaa Monoclonal Antibody Drugs For Cancer Product Market Performance
10.10.4 Merck Kgaa Business Overview
10.10.5 Merck Kgaa Recent Developments
10.11 Seagen
10.11.1 Seagen Basic Information
10.11.2 Seagen Monoclonal Antibody Drugs For Cancer Product Overview
10.11.3 Seagen Monoclonal Antibody Drugs For Cancer Product Market Performance
10.11.4 Seagen Business Overview
10.11.5 Seagen Recent Developments
10.12 Eli Lilly
10.12.1 Eli Lilly Basic Information
10.12.2 Eli Lilly Monoclonal Antibody Drugs For Cancer Product Overview
10.12.3 Eli Lilly Monoclonal Antibody Drugs For Cancer Product Market Performance
10.12.4 Eli Lilly Business Overview
10.12.5 Eli Lilly Recent Developments
10.13 Ono Pharmaceutical
10.13.1 Ono Pharmaceutical Basic Information
10.13.2 Ono Pharmaceutical Monoclonal Antibody Drugs For Cancer Product Overview
10.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs For Cancer Product Market Performance
10.13.4 Ono Pharmaceutical Business Overview
10.13.5 Ono Pharmaceutical Recent Developments
10.14 Pfizer
10.14.1 Pfizer Basic Information
10.14.2 Pfizer Monoclonal Antibody Drugs For Cancer Product Overview
10.14.3 Pfizer Monoclonal Antibody Drugs For Cancer Product Market Performance
10.14.4 Pfizer Business Overview
10.14.5 Pfizer Recent Developments
10.15 Regeneron
10.15.1 Regeneron Basic Information
10.15.2 Regeneron Monoclonal Antibody Drugs For Cancer Product Overview
10.15.3 Regeneron Monoclonal Antibody Drugs For Cancer Product Market Performance
10.15.4 Regeneron Business Overview
10.15.5 Regeneron Recent Developments
10.16 Innovent
10.16.1 Innovent Basic Information
10.16.2 Innovent Monoclonal Antibody Drugs For Cancer Product Overview
10.16.3 Innovent Monoclonal Antibody Drugs For Cancer Product Market Performance
10.16.4 Innovent Business Overview
10.16.5 Innovent Recent Developments
10.17 Hengrui Medicine
10.17.1 Hengrui Medicine Basic Information
10.17.2 Hengrui Medicine Monoclonal Antibody Drugs For Cancer Product Overview
10.17.3 Hengrui Medicine Monoclonal Antibody Drugs For Cancer Product Market Performance
10.17.4 Hengrui Medicine Business Overview
10.17.5 Hengrui Medicine Recent Developments
11 Monoclonal Antibody Drugs For Cancer Market Forecast By Region
11.1 Global Monoclonal Antibody Drugs For Cancer Market Size Forecast
11.2 Global Monoclonal Antibody Drugs For Cancer Market Forecast By Region
11.2.1 North America Market Size Forecast By Country
11.2.2 Europe Monoclonal Antibody Drugs For Cancer Market Size Forecast By Country
11.2.3 Asia Pacific Monoclonal Antibody Drugs For Cancer Market Size Forecast By Region
11.2.4 South America Monoclonal Antibody Drugs For Cancer Market Size Forecast By Country
11.2.5 Middle East And Africa Forecasted Sales Of Monoclonal Antibody Drugs For Cancer By Country
12 Forecast Market By Type And By Application (2026-2033)
12.1 Global Monoclonal Antibody Drugs For Cancer Market Forecast By Type (2026-2033)
12.1.1 Global Forecasted Sales Of Monoclonal Antibody Drugs For Cancer By Type (2026-2033)
12.1.2 Global Monoclonal Antibody Drugs For Cancer Market Size Forecast By Type (2026-2033)
12.1.3 Global Forecasted Price Of Monoclonal Antibody Drugs For Cancer By Type (2026-2033)
12.2 Global Monoclonal Antibody Drugs For Cancer Market Forecast By Application (2026-2033)
12.2.1 Global Monoclonal Antibody Drugs For Cancer Sales (K Mt) Forecast By Application
12.2.2 Global Monoclonal Antibody Drugs For Cancer Market Size (M Usd) Forecast By Application (2026-2033)
13 Conclusion And Key Findings
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.